Eli Lilly and Company is embarking on a significant acquisition spree, exemplified by its recent agreement to acquire Kelonia Therapeutics…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
Over the past 16 months, Chinese-domiciled biopharmaceutical companies have emerged as significant players in the global drug development landscape, participating…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, currently riding an unprecedented wave of success fueled by its GLP-1 franchise, has announced its intent…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
Over the past 16 months, Chinese-domiciled biotechnology companies have emerged as significant players in the global pharmaceutical landscape, securing approximately…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, currently buoyed by the explosive success of its GLP-1 franchise, has announced its intent to acquire…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
The majority of these high-value collaborations, roughly half, involved firms of U.S. origin, predominantly structured as mergers and acquisitions (M&A).…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, a pharmaceutical giant currently experiencing unprecedented growth driven by its blockbuster GLP-1 agonists, has announced its…
Read More
Chinese Firms Landed 6 of 26 Major Pharma Deals in 16 Months, Worth $53 Billion
Over the past 16 months, Chinese-domiciled biopharmaceutical companies have emerged as formidable players in the global drug development landscape, securing…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company is embarking on a significant acquisition drive, highlighted by its agreement to acquire Kelonia Therapeutics, a…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
Over the past 16 months, Chinese-domiciled biotechnology companies have emerged as formidable forces in the global pharmaceutical landscape, featuring prominently…
Read More
